Aditxt is a biotech company. Co. is developing biotechnologies focused on improving the health of the immune system through immune mapping and reprogramming. Co.'s immune mapping technologies are designed to provide a personalized profile of the immune system. Co.'s immune reprogramming technologies are designed to retrain the immune system to induce tolerance with the objectives of addressing rejection of transplanted organs as well as ameliorate autoimmune diseases and allergies. These programs are in the pre-clinical stage with one product candidate slated for GMP manufacturing (clinical grade material) and toxicology studies in preparation for clinical trials. The ADTX stock yearly return is shown above.
The yearly return on the ADTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ADTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|